chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Initial report received from a healthcare professional on 28 May 2010: This patient was vaccinated with MENVEO (batch number: unknown) unknown dose, intramuscularly on 27 May 2010. It was reported that, the patient received only intramuscular diluent on 27 May 2010 and not administered lyophilized portion. No any adverse event occurred. The outcome of the event was not reported. Follow up report received from a healthcare professional on 08 Jun 2010: The reporter found an extra vial of powder in the box and that is how he knew that someone received only the diluent. The reporter had no idea as who is that patient. No further information provided.
Patient states she became short of breath, "felt funny" pre patient several 2-3 hours after receiving FLUZONE. No known allergies reported . Hypertension for which she takes DIVETIC and cerebrovascular accident in September 2001. cerebrovascular accident occurred during pregnancy, treated at Kingston City Hospital ER with BENADRYL and steroids. 3 times for "racing heart" per patient report. She vomited in the ER, "phlegm" per patient. Was sent home after several hours with diagnosis of "allergic reaction". But ER doctor did not state a cause or discharge instructions, per patient. Patient stated she did speak to her physician after being seen and made her aware of ER visit and reaction. Will follow up with MD re: any further problems or distress. May contact vaccine compensation to inquire about monetary compensation if eligible.
Patient reported having severe flu-like symptoms including fever, chills, and headache. He stated he could not get out of bed for a day but the symptoms resolved after that day.
Still have mark from injection and after hearing from another who just received their shot, took a magnet and it sticks to my arm at the location of the injection.  Want to know why this is.  It does not stick anywhere else on my body, I have no swelling, not sweating and the magnet does not stick to my husband, who did not take the vaccine.
This is a spontaneous report from a contactable consumer or other non hcp. A female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; Lot number unknown), via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient experienced GI symptoms (gastrointestinal disorder) on an unspecified date with outcome of unknown. The action taken in response to the event (s) for bnt162b2 was not applicable. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Racing Mind/Thoughts, Headaches. These symptoms started the afternoon of 06/17/2015. Mother and Pt returned to Dr office on 06/18/2015 due to symptoms. Advised pt to rest and avoid overstimulation of mental activity until symptoms resolve. Also to stay hydrated and can take OTC Ibuprofen per product label as needed. Spoke with Patients mother and patient on 06/19/2015 AM and Patient stated doing better and symptoms were not as severe.
Narrative:  Patient discharged home after 2 days in hospital. PLT improved with steroids
The day after I received the vaccine, I felt pretty ill. It only lasted for about a day and a half. I experienced a stroke about three weeks ago. I was admitted to Wytheville County Hospital for a week and a half. I had a MRI and had blood drawn to determine that I experienced a stroke.
faintly feeling; got nauseated; rapid heart beat; shortness of breath; swelling tongue; hard to swallow; fatigue; no energy; That night felt numb all over, hands feet face; severe headache; This is a spontaneous report from a contactable consumer (patient).   A 75-years-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 06Feb2021 (Batch/Lot number was not reported) as single dose for covid-19 immunisation.   Medical history included cardiac operation in 2008. The patient's concomitant medications were not reported.   The patient experienced faintly feeling (dizziness) (non-serious) on an unspecified date with outcome of unknown , got nauseated on an unspecified date with outcome of unknown , that night felt numb all over, hands feet face (hypoaesthesia) (non-serious) on 06Feb2021 with outcome of unknown , severe headache (non-serious) on 06Feb2021 with outcome of unknown , rapid heart beat (heart rate increased) (non-serious) on an unspecified date with outcome of unknown , shortness of breath (non-serious) on an unspecified date with outcome of unknown , swelling tongue (swollen tongue) (non-serious) on an unspecified date with outcome of unknown , hard to swallow (dysphagia) (non-serious) on an unspecified date with outcome of unknown , fatigue on an unspecified date with outcome of unknown , no energy (asthenia) (non-serious) on an unspecified date with outcome of unknown.      Information on Lot /Batch Number has been requested.
Headache, blurred vision, dehydration, weakness, dizziness, elevated D-dimer, Shortness of breath
Given the vaccine on day 31 days of expiry; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Given the vaccine on day 31 days of expiry) in a 21-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Oct-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Given the vaccine on day 31 days of expiry). On 14-Oct-2021, EXPIRED PRODUCT ADMINISTERED (Given the vaccine on day 31 days of expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications was provided. No treatment information was provided.   This case was linked to MOD-2021-353224, MOD-2021-353228, MOD-2021-353241, MOD-2021-353249, MOD-2021-353252, MOD-2021-353569, MOD-2021-353578, MOD-2021-353593, MOD-2021-353262 (Patient Link).
numbness on right side of his body; tingling on right side of body; burning sensation on right side of his body; neurological pain; could not able to walk; could not take shower and could not drive car; severe ache all over the body like head to toe; This spontaneous case was reported by a patient (subsequently medically confirmed) and describes the occurrence of HYPOAESTHESIA (numbness on right side of his body), PARAESTHESIA (tingling on right side of body), BURNING SENSATION (burning sensation on right side of his body), NEURALGIA (neurological pain) and GAIT INABILITY (could not able to walk) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Multiple sclerosis since September 2007 and Allergy. Concomitant products included CETIRIZINE HYDROCHLORIDE (ZYRETIC) for Allergy, FINGOLIMOD HYDROCHLORIDE (GILENYA) for Multiple sclerosis, METFORMIN, GLIPIZIDE and ATORVASTATIN CALCIUM (LIPITOR) for an unknown indication.    On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Mar-2021, the patient experienced HYPOAESTHESIA (numbness on right side of his body), PARAESTHESIA (tingling on right side of body), BURNING SENSATION (burning sensation on right side of his body), NEURALGIA (neurological pain), GAIT INABILITY (could not able to walk), LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (could not take shower and could not drive car) and MYALGIA (severe ache all over the body like head to toe). The patient was treated with PREDNISONE at a dose of UNK dosage form. At the time of the report, HYPOAESTHESIA (numbness on right side of his body), PARAESTHESIA (tingling on right side of body), BURNING SENSATION (burning sensation on right side of his body), NEURALGIA (neurological pain), GAIT INABILITY (could not able to walk), LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (could not take shower and could not drive car) and MYALGIA (severe ache all over the body like head to toe) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Fever/headache/runny nose/congestion/sneezing. Symptoms started after recent of 1st dose of LAIV, quadrivalent. LApan immunization activity. 0/19/2015 seen in ER - CT head no acute intracranial findings. Lumbar puncture completed - CSF findings unremarkable. 11/17/2015 - Neurology consult - migraine management plan with Botox injections.  Continued headaches. Now seeing neurologist.
C/O dizziness for 4 days, nausea, afebrile, body aches.
Was supposed to give patient shingles vaccination and instead gave varicella vaccination (from the state supply vaccinations).
Given the moderna vaccine sooner than scheduled; A spontaneous report was received from a nurse concerning a patient who was participating in the mRNA-1273 Emergency Use Program and received the vaccine sooner than scheduled.   The patient's medical history was not provided. No relevant concomitant medications were reported.   On 05-Jan-2021, prior to the onset of the event, the patient received their second of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection.   The reporter reported that the patient received vaccine sooner than scheduled. The first dose was administered on 23-Dec-2020 and the second dose on 05 Jan 2021.   No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not provided.   The event inappropriate schedule of product administration was considered resolved on 05 Jan 2021.  The reporter did not provide an assessment of the event inappropriate schedule of product administration.; Reporter's Comments: This report refers to a case of Inappropriate schedule of product administration for mRNA-1273, lot # unknown. There were no reported AEs associated with this case of Inappropriate schedule of product administration.
shortly after injection the patient felt a sharp pain through arm and neck, felt very dizzy and could not stand
At 10:12 am, Client c/o of sore throat, tightness in throat that relieve quickly, nausea, dry heaves, flushed, light headed and dizziness.  Called for EMT. They arrive at 10:25 am and transported her to the local hospital for observation.   01/06/21-Treatment in hospital blood draw, medications given Zofran, Decadron, Benadryl, and Pepcid, and IV fluids.  Discharged home at 1244.
Tingling in her feet, fingertips, lower arm and calves of her legs; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 58 year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), administered in arm left, administration date 29Jan2021 (Lot number: EL9265) at the age of 58 years as dose 1, single for COVID-19 immunisation. Relevant medical history included: "Cancer", start date: Apr2020 (ongoing); "Chemo" (unspecified if ongoing), notes: she finished chemo in Oct and cut chemo short a couple of rounds because of issues with neuropathy; "Radiation" (unspecified if ongoing), notes: radiation in Jan for 6 weeks & half way through she got her 1st  dose of the vaccine on 29Jan2021; "For bones" (unspecified if ongoing). Concomitant medication(s) included: VITAMIN D taken for bone disorder, start date: 11Jan2021 (ongoing); COD-LIVER OIL taken for bone disorder, start date: 11Jan2021.  The following information was reported: PARAESTHESIA (non-serious), outcome "not recovered", described as "Tingling in her feet, fingertips, lower arm and calves of her legs". Therapeutic measures were taken as a result of paraesthesia. The patient stated that the events started after the first dose and has been ongoing. She said that she was in the middle of radiation treatment and was no longer on chemotherapy. She had neuropathy symptoms in Oct2020 during her treatment with chemotherapy. She said that it had been improving and she had not had any tingling in her back or upper arms and that type of a thing. It was more in the feet, calves, hands, and lower arms she did have from the chemo.   No follow-up attempts are possible. No further information is expected.
Emotional ill, intense pain, chilly, suffering the itchiness, temperature is high, awful headache, rashes, red, swollen blistered and sleepless night. My primary doctor prescribed the antibiotic medicine for my slight wound then shingles vaccine shot.
Chronic spontaneous urticaria 10 days after receiving my Covid 19 booster. Started January 1st of 2022 and has not stopped occurring since onset. Was aggravated by cold initially but now hives occur in the evening around 9pm every night. Antihistamines seem to have no effect.
Systemic: Dizziness / Lightheadness-Mild, Systemic: Fainting / Unresponsive-Mild, Systemic: Hypotension-Mild, Systemic: Visual Changes/Disturbances-Mild, Additional Details: patient had some dizziness, pale color, fell out of chair and on to floor after receiving shot.  patient was alert and responsive,  sat down again and held on to counter for about 30 minutes. patient stated he no longer felt dizzy or strange.  I took patient's BP and it was 99/58 with HR of 55 bpm, patient stated he is very fit and this was normal for him.  I allowed patient to leave at that point, contacted him on 6/22, he said he was well and had experienced no additional issues after leaving.
Rash on lower left arm consisting of raised bumps - no vesicles seen around site of injection.  Patient applied hydrocortisone cream to rash and it has been gradually improving over past week.  Came in to pharmacy today (7-19), rash still visible but patient reports it is much improved.  No itching.
experienced  pulmonary embolism with booster.In the hospital currently intubated; experienced pulmonary embolism with booster; experienced pulmonary embolism with booster; This is a spontaneous report from a non-contactable consumer(patient) or other non hcp. A female patient of an unspecified age received third dose of bnt162b2(PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, batch/lot number was not reported), via an unspecified route of administration on an unspecified date as single dose for COVID-19 immunisation. Medical history included type 1 diabetes mellitus. Concomitant medication included insulin. The historical vaccines include bnt162b2(PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, batch/lot number was not reported), via an unspecified route of administration on an unspecified date as DOSE 2, SINGLE and via an unspecified route of administration on an unspecified date as DOSE 1, SINGLE for COVID-19 immunisation. On an unspecified date the patient experienced coagulation after first two shots and experienced pulmonary embolism with booster. The patient was taken to emergency care and currently in the hospital, intubated after first two IV treatment. The patient was hospitalised for 5days. On an unspecified date patient developed experienced pulmonary embolism with booster (immunisation) and experienced pulmonary embolism with booster (off label use). The event outcome for pulmonary embolism was reported as recovering. The event outcome for experienced pulmonary embolism with booster (immunisation) and experienced pulmonary embolism with booster (off label use) was reported as unknown. The event resulted in: Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event)  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow-up.
Soreness at injection site; mild nerve feeling all the way down to my elbow in the injected arm; minor version of what shingles feels like; This case was reported by a consumer via call center representative and described the occurrence of shingles in a 60-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   In January 2021, the patient received the 1st dose of Shingrix. In January 2021, less than a day after receiving Shingrix, the patient experienced shingles and nerve pain. On an unknown date, the patient experienced injection site pain. On an unknown date, the outcome of the shingles and nerve pain were recovered/resolved and the outcome of the injection site pain was not recovered/not resolved.   It was unknown if the reporter considered the shingles, injection site pain and nerve pain to be related to Shingrix.  Additional details were provided as follows: The patient reported for herself. The patient received Shingrix in the left arm.  The patient had soreness at the injection site. Within hours of vaccination, she experienced a mild nerve feeling all the way down to elbow in the injected arm that she described as a minor version of what shingles feels like.  The reporter did not consent to follow-up and did not provide consent to follow-up with Healthcare professional.
Information has been received from a consumer concerning her 6 months old grandson who was taking "alimentum due to lactose intolerance and "something for reflux" who between 20-May-2009 and 25-May-2009 was vaccinated orally with his first dose of ROTATEQ, on an unspecified date received his second dose of ROTATEQ and on 06-Oct-2009 received orally his third dose of ROTATEQ. Concomitant therapy included "something for the reflux, maybe PRILOSEC", and other unspecified vaccines "that were due at 6 months of age but they were not live vaccines". According to the reporter, the patient received his third dose of ROTATEQ and on 07-Oct-2009 had horrible smelling dark bowel movements. It was also reported that the stools were soft and very loose but not runny and green in color. The grandson had 2-5 bowel movements every day. The reporter also stated there was no fever. The pediatrician office told the mother of the patient on 08-Oct-2009 that it was probably rotavirus. The reporter stated that the consumer had no problems with the first or second dose of ROTATEQ. At the time of the report the patient had not recovered. No diagnostic tests were performed. Additional information has been requested.
No adverse effect reported; one patient received an improperly stored VARIVAX; This spontaneous report was received from a registered nurse referring to a 3-year-old patient of unknown gender. No information was provided regarding the patient's medical history, concurrent conditions or concomitant medications.  On 28-AUG-2019, the patient was vaccinated with an improperly stored varicella virus vaccine live (oka/merck) (VARIVAX) lot # R006221 with expiration date 29-FEB-2020 or R029517 with expiration date 14-OCT-2020 (reported as 14 of unknown month 2020) (dosage schedule, route and anatomical location were not reported), for prophylaxis (incorrect product storage). The vaccine was reconstituted with properly stored sterile diluent. No adverse effects were reported.  On 12-AUG-2019 and 13-AUG-2019, administered doses of vaccine experienced temperature excursion of -14 degrees Celsius (C) to -10 C (-11.91 C) for 8 hours. There was no previous temperature excursion. Digital data logger was involved.
15 year old received 1st dose of Moderna COVID-19 vaccination; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (15 year old received 1st dose of Moderna COVID-19 vaccination) in a 15-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003F21A) for COVID-19 vaccination.     Concomitant products included FLUTICASONE for an unknown indication.    On 23-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Aug-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (15 year old received 1st dose of Moderna COVID-19 vaccination). On 23-Aug-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (15 year old received 1st dose of Moderna COVID-19 vaccination) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment medication was provided.
passing out; blood pressure of 70/40; Feeling hot; Sweaty; Dizziness; Lethargy; Sore arm; Achy all over; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of LOSS OF CONSCIOUSNESS (passing out) in a 56-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 21-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Apr-2021, the patient experienced LOSS OF CONSCIOUSNESS (passing out) (seriousness criterion medically significant), BLOOD PRESSURE DECREASED (blood pressure of 70/40), FEELING HOT (Feeling hot), HYPERHIDROSIS (Sweaty), DIZZINESS (Dizziness), LETHARGY (Lethargy), PAIN IN EXTREMITY (Sore arm) and MYALGIA (Achy all over). On 21-Apr-2021, LOSS OF CONSCIOUSNESS (passing out) had resolved. At the time of the report, BLOOD PRESSURE DECREASED (blood pressure of 70/40), FEELING HOT (Feeling hot), HYPERHIDROSIS (Sweaty), DIZZINESS (Dizziness), LETHARGY (Lethargy), PAIN IN EXTREMITY (Sore arm) and MYALGIA (Achy all over) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications reported.  Patient reports that paramedics had to come after he passed out.   Treatment of the events included acetaminophen.  Company comment: This case concerns a 56-year-old male with a serious unexpected event of loss of consciousness, and nonserious unexpected blood pressure decreased, feeling hot, hyperhidrosis, dizziness, lethargy and expected pain in extremity. Event onset the same day as first dose mRNA-1273. Events resolved. Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
cardio-resp failure; VS P120, R53, BP 108/62, t99.2, weight on discharge was 2.8kg & weight on admission was 3.3kg; HEENT exam revealed pupils equal, round & reactive to light; lungs w/coarse breath sounds; mild cyanosis; pt pale, emesis;
1st dose on 2021, never had her 2nd dose; This case was reported by a consumer via call center representative and described the occurrence of incomplete course of vaccination in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received in October 2021).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 26-SEP-2022 Reporter's Comments: The patient self-reported this case. The patient received first dose of Shingrix, but never receive her second dose. The reporter did not wish to provider her date of birth.  The patient indicates she would get the second dose. VAERS detail was reported for 1st dose. The reporter consent to follow up. Additional Supportive Information: Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination.